Rheonix Sees Automation as Key to Expanding Molecular Testing

Gregory Galvin, Ph.D.,CEO, Rheonix Richard Montagna, Ph.D., SVP, scientific and clinical affairs, Rheonix The molecular firm Rheonix (Ithaca, N.Y.) developed a microfluidic platform capable of fully automating multiplex molecular testing—from raw sample to result—at a lower cost. One novel feature of the platform is the Rheonix CARD (Chemistry And Reagent Device) that fully automates sample preparation for molecular testing for a wide array of diagnostic applications including next-generation sequencing (NGS). Rheonix believes the platform’s small size, affordability, and flexibility will enable the expansion of molecular testing applications both in the clinical realm, as well as in the food and beverage industry. DTET recently spoke to Gregory Galvin, Ph.D., Rheonix’s CEO, as well as Richard Montagna, Ph.D., senior vice president of scientific and clinical affairs, regarding the company’s technology and its commercial launch. Rheonix believes the platform’s small size, affordability, and flexibility will enable the expansion of molecular testing applications both in the clinical realm, as well as in the food and beverage industry. DTET recently spoke to Gregory Galvin, Ph.D., Rheonix’s CEO, as well as Richard Montagna, Ph.D., senior vice president of scientific and clinical affairs, regarding the company’s technology and its commercial launch. How can Rheonix’s platform expand the […]